Mumbai: Pharma major Lupin announced the launch of Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine® tablets. It is indicated for the treatment of chorea associated with Huntington’s disease.
Xenazine® tablets had annual sales of $153 million in the US (IQVIA MAT September 2018). Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders
Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization and the 8th largest generics pharmaceutical company in terms of revenues globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market; 3rd largest Indian pharmaceutical company by global revenues ; 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market ).